(HRTX) Heron Therapeutics, Inc. Business Model Canvas Research

Heron Therapeutics, Inc. relies on clinical investigators and CROs because its development assets need multi-site trials to generate efficacy and safety data for FDA review. CROs help Heron Therapeutics, Inc. speed enrollment, monitor sites, and run study ops with lower internal overhead.

• Investigators deliver review-ready safety data
• CROs manage enrollment and monitoring
• Multi-site trials reduce execution risk

Payers and formulary decision-makers are critical for Heron Therapeutics, Inc. because access rules decide whether hospital-administered therapies are used in practice. Heron must work with payer teams, pharmacy and therapeutics committees, and reimbursement staff to secure coverage and reduce step edits or denials.

• Coverage drives real-world use
• Hospital committees shape formulary access
• Reimbursement teams affect adoption speed

Heron Therapeutics, Inc.’s commercial supply and quality management covers production planning, QA, and lot release for sterile injectables, where every batch must pass tight sterility and consistency checks. In 2025, reliable supply stayed critical because hospital buyers favor suppliers that can keep product available without quality slips.

• Plans production to avoid stockouts
• Checks sterility and batch consistency
• Releases lots only after QA approval

Heron Therapeutics, Inc. uses its sales team to reach oncology and surgical care stakeholders, while market access teams work to win formulary placement and reimbursement. Medical education then helps clinicians use the products correctly by covering dosing, efficacy, and safety, which supports adoption in hospital and outpatient settings.

• Promotes to oncology and surgery teams
• Supports formulary and reimbursement wins
• Trains clinicians on dose and safety

Heron Therapeutics, Inc.’s regulatory dossiers and clinical data are core assets because approved labels, pivotal trial results, and safety databases support commercialization, lifecycle management, and new filings. They also help win payer and provider adoption by backing value, dosing, and safety claims across products like ZYNRELEF and APONVIE.

• Approved labels drive sales support
• Trial data backs new filings
• Safety data helps payer access

Heron Therapeutics, Inc.'s commercial and medical affairs teams are key resources for hospital-led specialty sales: field reps manage hospital accounts, formulary access, and clinician education, while medical affairs handles scientific exchange and data requests. In FY2024, Heron’s revenue was driven by this institutional model, so access work and clinical support directly affect uptake.

• Hospital account support

• Formulary access

• Clinician education

• Scientific data responses

Heron Therapeutics, Inc. focuses on operational convenience for providers by using single-dose products that cut repeat administrations, simplify workflows, and reduce medication handling in busy inpatient and outpatient settings. ZYNRELEF, for example, is designed as a 1-dose, 72-hour postsurgical pain option, which can save nursing time and lower process steps.

• 1 dose instead of repeated dosing
• Less nursing time and handling
• Fits high-volume surgical workflows

Heron Therapeutics, Inc. builds specialty care formulations for oncology, surgery, and acute care, where tight symptom control matters and treatment is often protocol-driven. Its products are designed for hospital and institutional use, so the value proposition is clear: consistent, on-site relief that fits clinical pathways.

• 3 care settings: oncology, surgery, acute care
• Built for institutional treatment protocols
• Focuses on reliable symptom control

Heron Therapeutics, Inc. tracks adverse events and product complaints after launch across its 4 marketed injectable brands, because safety systems are standard for approved injectable therapies. Ongoing pharmacovigilance follow-up helps protect patient trust, support FDA compliance, and keep product use on track.

• Post-launch AE and complaint monitoring
• Required safety controls for injectables
• Supports confidence and compliance

Heron Therapeutics, Inc. relies on wholesalers to handle order status and inventory support, keeping products moving through hospital supply chains for time-sensitive oncology and surgical use. In 2024, the Company reported $109.2 million in net product sales, so fast partner service helps protect access and fill rates.

• Wholesalers manage order tracking.
• Inventory support keeps hospitals stocked.
• Speed matters in oncology and surgery.

Heron Therapeutics, Inc. relies on wholesalers and distributors to push product into hospital and clinic inventory systems, which gives broad U.S. reach and steady replenishment. This channel also helps smaller facilities that lack strong purchasing teams or direct-buy systems, so access stays consistent.

• Wide geographic coverage
• Supports replenishment cycles
• Helps smaller facilities

In 2025, this channel stayed key for institutional access because large distributors still sit between manufacturers and care sites.

GPO and IDN contracts can decide whether Heron Therapeutics, Inc. products get stocked and made preferred, so one win can spread across many sites fast. This matters in hospital specialty pharmacy, where about 70% of U.S. hospitals buy through GPOs and IDNs can standardize orders across a whole system.

• Drives formulary access
• Scales across many hospitals
• Key for specialty pharmacy

Ambulatory surgery centers need fast pain and nausea control so patients can leave the same day, which makes single-dose products a good fit for Heron Therapeutics, Inc. These sites value simple workflows, fewer repeat doses, and less nursing time spent on re-dosing.

• Supports same-day discharge
• Fits single-dose use
• Reduces workflow steps
• Lowers re-dosing needs

Pharmacy and formulary committees are key gatekeepers for Heron Therapeutics, Inc. at the facility level: they review clinical data, budget impact, and protocol fit before broader use starts. Their approval can decide whether a product reaches standard hospital use, so evidence, safety, and cost must align.

• Control facility-level access
• Assess evidence and budget impact
• Require protocol fit
• Approve broad use first

Heron Therapeutics, Inc. general and administrative costs cover headquarters work like finance, legal, HR, and IT, plus public-company compliance from its San Diego base. These are corporate overhead costs: they support the business, but they do not directly create product revenue.

• Finance, legal, HR, IT
• Public-company overhead
• No direct product revenue

Heron Therapeutics, Inc. bears steady regulatory, legal, and IP costs because its 2 marketed injectable products need FDA oversight, batch-release controls, and label-compliance work. Patent defense also stays costly, since platform-based therapies rely on protecting formulation, delivery, and method-of-use claims to defend pricing and market share.

• 2 marketed injectables raise oversight costs
• FDA compliance adds ongoing expense
• Patent defense protects platform value

Heron Therapeutics, Inc. can earn license and royalty income from out-licensed rights or partnered territories, but this is usually a smaller stream than direct product sales. In specialty pharma, royalties often come as a percentage of partner net sales, so the revenue can be steady but tied to the partner’s commercial launch pace.

• Out-licensed rights create passive income.

• Partner territory sales drive royalties.

• Usually smaller than product revenue.

Heron Therapeutics, Inc. can earn non-product revenue from milestone and collaboration payments when a partner hits development or regulatory targets, so the stream is event-driven, not steady like product sales. In 2025, this type of revenue remained tied to specific partner progress, which makes it harder to forecast than recurring drug sales.

• Triggered by regulatory or development events
• Non-product revenue, not recurring sales
• Lumpy and harder to predict